TAP1 and neoplasm: While GBM tumours frequently exploit immune evasion mechanisms such as PD-L1 overexpression, MHC-I downregulation, and impaired antigen presentation via TAP1/TAP2 suppression, translation of these findings into effective immune checkpoint inhibitor (ICI) therapies has proven challenging [62].